扫码登录小狗阅读
Construction of high quality ultrathin lanthanide oxyiodide nanosheets for enhanced CT imaging and anticancer drug delivery to efficient cancer theranostics.
构建高质量超薄镧系氧化二烯纳米片,用于增强 CT 成像和抗癌药物递送至高效癌症治疗学。
- 影响因子:9.85
- DOI:10.1016/j.biomaterials.2019.119670
- 作者列表:"Xu L","Xue Y","Xia J","Qu X","Lei B","Yang T","Zhang X","Li N","Zhao H","Wang M","Luo M","Zhang C","Du Y","Yan C
- 发表时间:2020-02-01
Abstract
:Two-dimensional (2D) ultrathin nanomaterials have shown extensive attention and potential biomedical applications in cancer theranostics. Herein, for the first time, we report the synthesis of monodisperse ultrathin lanthanum oxyiodide (LaOI) nanosheets with a thickness of merely 3 nm based on a facile wet chemistry strategy. By tuning the solvent composition and molar ratios of the precursors, we can modulate the shape and thickness of the nanosheets. Furthermore, a series of ultrathin lanthanide oxyiodides are synthesized by this method with tunable morphology. LaOI nanosheets as drug delivery platform showed ultrahigh anticancer doxorubicin (DOX) loading capacity (300 wt%) and pH-responsive release behaviour, as well as excellent cellular biocompatibility and efficiently intracellular nucleus delivery of DOX. LaOI with low dose DOX demonstrate enhanced cancer cell killing ability in vitro compared with DOX. The intravenous melanoma model shows that LaOI with low dose (1 mg mL-1) could significantly inhibit the tumor growth without side toxicity, relative to pure DOX. In addition, LaOI nanosheets also act as high resolution contrast agent for enhanced X-ray computed tomography imaging relative to the commercial iohexol. In summary, the LaOI nanosheets could serve as a competitive safe and low dose drug delivery platform for highly efficiently cancer imaging and therapy.
摘要
: 二维 (2D) 超薄纳米材料在癌症治疗中表现出广泛的关注和潜在的生物医学应用。在此,我们首次报道了基于简便的湿化学策略合成厚度仅为 3 nm 的单分散超薄镧 (LaOI) 纳米片。通过调节前体的溶剂组成和摩尔比,我们可以调节纳米片的形状和厚度。此外,通过这种方法合成了一系列具有可调形貌的超薄镧系氧化物。LaOI 纳米片作为药物递送平台显示超高抗癌阿霉素 (DOX) 负载能力 (300 wt %) 和 pH 响应释放行为, 以及优良的细胞生物相容性和 DOX 的有效胞内细胞核递送。低剂量 DOX 的 LaOI 证明与 DOX 相比,体外癌细胞杀伤能力增强。静脉注射黑色素瘤模型显示,与单纯 DOX 相比,低剂量 LaOI (1 mg mL-1) 可显著抑制肿瘤生长,且无副作用。此外,相对于商业碘海醇,LaOI 纳米片还充当了增强 x射线计算机断层扫描成像的高分辨率造影剂。总之,LaOI 纳米片可以作为一个有竞争力的安全和低剂量的药物递送平台,用于高效的癌症成像和治疗。
小狗阅读
帮助医生、学生、科研工作者解决SCI文献找不到、看不懂、阅读效率低的问题。提供领域精准的SCI文献,通过多角度解析提高文献阅读效率,从而使用户获得有价值研究思路。
METHODS::In colorectal cancer (CRC), hepatic arterial infusion (HAI) chemotherapy may convert primarily unresectable CRC liver metastases (CLM) into resectability, although the risk of metastatic recurrence remains high after CLM ablation. We investigated the role of antitumour immunity invoked by first-line oxaliplatin-HAI for long-term CLM outcome. In a prospective study cohort of primarily unresectable CLM, we assessed patients' fms-related tyrosine kinase 3 ligand (FLT3LG) in serum, reflecting opportune intratumoural immune activity, at baseline and following 1-3 sequences of oxaliplatin-HAI. The end points were CLM resectability and overall survival. Patients who presented an immediate twofold increment of circulating FLT3LG during the treatment and at its completion were scored as CLM resectable (16.4% with both features), were alive at final follow-up 8-12 years later. All patients experienced FLT3LG increase during the treatment course, but those who remained unresectable or had the disease converted but presented a slow and gradual FLT3LG accretion, later died of the metastatic disease. These data provide further support to our previous findings that tumour-directed immunity invoked by oxaliplatin-containing therapy predicts excellent outcome of early advanced CRC if macroscopic tumour ablation is rendered possible by the 'classic' tumour response to the cytotoxic treatment.
METHODS::Prostate cancer is one of the primary causes of death around the world. As an important drug, flutamide has been used in the clinical diagnosis of prostate cancer. However, the over dosage and improper discharge of flutamide could affect the living organism. Thus, it necessary to develop the sensor for detection of flutamide with highly sensitivity. In this paper, we report the synthesis of lanthanum cobaltite decorated halloysite nanotube (LCO/HNT) nanocomposite prepared by a facile method and evaluated for selective reduction of flutamide. The as-prepared LCO/HNT nanocomposite shows the best catalytic performance towards detection of flutamide, when compared to other bare and modified electrodes. The good electrochemical performance of the LCO/HNT nanocomposite modified electrode is ascribed to abundant active sites, large specific surface area and their synergetic effects. Furthermore, the LCO/HNT modified electrode exhibits low detection limit (0.002 μM), wide working range (0.009-145 μM) and excellent selectivity with remarkable stability. Meaningfully, the developed electrochemical sensor was applied in real environmental samples with an acceptable recovery range.
METHODS::Several studies have indicated that cancer-associated fibroblasts (CAFs) could promote cancer progression in many malignancies. However, the mechanism by which CAFs promote the growth and metastasis of lung cancer remains poorly defined. In the present study, CAFs and normal fibroblasts (NFs) were isolated from human lung cancer and adjacent tissue. The data showed that the conditional medium (CM) of CAFs could increase the proliferation, migration and invasion of lung cancer cells. Vascular cell adhesion molecule-1 (VCAM-1) showed a higher expression in CAF-CM than NF-CM, and blocking VCAM-1 in CAF-CM attenuated the proliferation and invasion of cancer cells. Further, the results showed that VCAM-1 secreted from CAFs activated AKT and MAPK signaling via receptor α4β1 integrin (very-late antigen (VLA)-4) in lung cancer cells. Moreover, CAFs promoted VCAM-1 expression and tumor growth in vivo. Additionally, bioinformatics analysis indicated a positive correlation on the CAF marker protein alpha-smooth muscle actin (α-SMA) and VCAM-1 expression, which was associated with a poor prognosis in lung cancer patients. These findings demonstrate that the VCAM-1 secreted from CAFs enhances growth and invasion by activating the AKT and MAPK signaling of lung cancer cells.